UBS Group Begins Coverage on Amneal Pharmaceuticals (NASDAQ:AMRX)

Equities research analysts at UBS Group started coverage on shares of Amneal Pharmaceuticals (NASDAQ:AMRX) in a note issued to investors on Friday, Marketbeat reports. The firm set a “buy” rating on the stock.

AMRX has been the subject of a number of other reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Truist Financial lifted their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $13.91 on Friday. The company has a market capitalization of $4.38 billion, a price-to-earnings ratio of 60.48 and a beta of 1.32. Amneal Pharmaceuticals has a one year low of $7.02 and a one year high of $15.42. The stock has a 50-day simple moving average of $13.23 and a 200 day simple moving average of $12.48.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Spire Wealth Management lifted its holdings in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares during the last quarter. Intech Investment Management LLC lifted its holdings in Amneal Pharmaceuticals by 1.2% in the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after acquiring an additional 1,159 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in Amneal Pharmaceuticals by 1.6% in the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after acquiring an additional 1,569 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Amneal Pharmaceuticals by 2.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after acquiring an additional 1,582 shares during the last quarter. Finally, Comerica Bank lifted its holdings in Amneal Pharmaceuticals by 56.1% in the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after acquiring an additional 1,685 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.